STAT
APRIL 10, 2024
stood at 323 during the fourth quarter of last year — the highest figure reached since such data began being tracked in 2001 — underscoring growing concerns about patient harm across the country. The number of ongoing and active drug shortages in the U.S. The reasons are varied, although many remain a mystery.
STAT
APRIL 11, 2024
stood at 323 during the fourth quarter of last year — the highest figure reached since such data began being tracked in 2001 — underscoring growing concerns about patient harm across the country, STAT tells us. Unresolved The number of ongoing and active drug shortages in the U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
SEPTEMBER 13, 2022
While they may not have known it at the time, through their work Ehrlich and Metschnikow formed the cornerstone of modern immunology, including chemoreceptor and chemotherapy concepts that revolutionised blood cancer treatment over the following century. 1942 – Chemotherapy moves from trenches to treatment .
RX Note
JULY 18, 2023
External Links CDC - Enterobiasis Chemotherapy of enterobiasis (oxyuriasis), 2001 The Diagnosis and Treatment of Pinworm Infection, 2019 Discourage nail biting and finger sucking. Some people advocate frequent washing of cuddly toys and bed linen as well.
pharmaphorum
JUNE 8, 2021
Chemotherapy still accounted for 72.6% Chemotherapy still plays a significant role in oncology treatment, accounting for 72.6% While all of the top ten best-selling oncology drugs in the US in 2019 were innovative therapies, four out of the top ten best-selling oncology drugs in China were for conventional chemotherapy. “In
European Pharmaceutical Review
DECEMBER 12, 2023
IPH5201 is being investigated in a Phase II trial, MATISSE, in combination with durvalumab (anti-PD-L1) and chemotherapy, in patients with resectable early-stage NSCLC. Innate Pharma also developing IPH5201 in collaboration with AstraZeneca. He is a member of the company’s Executive Board.
Pharmaceutical Technology
FEBRUARY 13, 2023
The first concept for a PROTAC was published in 2001, and recently these protein degraders have gained rapid momentum as a promising novel modality. Faslodex will be administered in the control arm of the Phase III study, allowing for direct comparison between the two ER degraders.
Expert insights. Personalized for you.
355 
Let's personalize your content